Navigation Links
Cord Blood America Revenues Up 121 Percent in First Nine Months of 2007
Date:11/20/2007

LOS ANGELES, Nov. 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today revenues for the first nine months of 2007 topped $5.698 million, up 121 percent compared to revenues of $2.582 million in the same period in 2006.

Revenues for the three months ended September 30, 2007 totaled $1.654 million, up 44.7 percent compared to revenues of $1.143 million in the third quarter of 2006.

The Company posted a gross profit of $2.384 million in the first nine months of 2007 and a gross profit of $994,449 in the third quarter. This compares to 2006 nine-month gross profit of $527,070 and a third quarter gross profit in 2006 of $250,104.

"The significant increase in revenue is partially due to the accretive acquisitions Cord Blood America has made, which increased the number of umbilical cord samples, and increased marketing efforts," said Matthew Schissler, CEO. "We are posting results that should be recognized as significant achievements by the financial markets and by our investors."

One key point Mr. Schissler stressed is that the loss from operations for the quarter ended September 30, 2007 is only $67, 082, down significantly from $672,239 for the three months ended June 30, 2007. "We said we want to run operationally profitable. This number is the biggest key indicator that the management is committed to this goal," said Cord Blood America's CEO.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the indust
'/>"/>

SOURCE Cord Blood America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Rockynol Retirement Community ... Oct. 14. The $11 million project will include the ... cooked-to-order kitchen with full-service restaurant style dining. , “We ... first class Assisted Living apartments,” said Kara Hanzie, Rockynol ... highest quality of care and this investment is proof ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Final Cut Pro ... release of the Citrus theme for FCPX filmmakers . ... use to describe the Citrus theme” Says Christina Austin, CEO ... to look so professional.” , Citrus comes with all the ... the template are: four transitions for added style, a title ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
Breaking Medicine News(10 mins):Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... 3rd Advocacy Day, WASHINGTON, March 10 ... Lupus Research (ALR), on behalf of the 1.4,million ... the,disease to their Members of Congress. ALR Advocates ... asked their Members to,support lupus research funding through ...
... KENILWORTH, N.J., March 10 Schering-Plough,Corporation (NYSE: SGP ... presentation,by Fred Hassan, chairman and Chief Executive Officer, at ... Fla., on,Tuesday, March 18, at approximately 10:15 a.m. (ET). ... the integration of Organon,BioSciences N.V., acquired in November 2007., ...
... PORTLAND, Ore. A team of researchers at Oregon ... Louis have described for the first time the mechanism ... engineered and patented the potential to become ... The team described how their genetically modified enzyme, called ...
... Review found vets with the syndrome were more exposed ... News) -- A new scientific review finds a strong ... War illness suffered by many veterans. , The ... found in pesticides, nerve agents and in pills given ...
... SAN FRANCISCO, March 10 The Women,s ... Hickman, MD, was honored with,the prestigious Rose ... the,American Academy of Dermatology meeting held recently ... ), (Logo: http://www.newscom.com/cgi-bin/prnh/20080310/AQM132LOGO-b ), ...
... 10 The Women,s Dermatologic,Society (WDS) is pleased to ... took office at the recent WDS luncheon during the,American ... Dr.,Connolly moved into the presidential role from this past ... the past three years.,Mary P. Lupo, MD, served as ...
Cached Medicine News:Health News:Working Together for a Cure 2Health News:Working Together for a Cure 3Health News:Key found to breakthrough drug for clot victims 2Health News:Key found to breakthrough drug for clot victims 3Health News:Gulf War Illness Strongly Linked to Chemical Exposure 2Health News:Gulf War Illness Strongly Linked to Chemical Exposure 3Health News:Lynchburg, VA Dermatologist Janet G. Hickman, MD Honored With Rose Hirschler Award from Women's Dermatologic Society 2Health News:Suzanne M. Connolly, MD Named 2008-2009 President of Women's Dermatologic Society 2
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
(Date:10/20/2014)... PRINCETON, N.J. , Oct. 20, 2014 /PRNewswire/ ... Taiho Pharmaceutical Co., Ltd. ( Japan ... Administration (FDA) granted Fast Track designation for TAS-102 ... combination anticancer drug under investigation for the treatment ... the Company has initiated a rolling NDA submission ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... 2012 The U.S. Food and Drug Administration today ... by W.L. Gore and Associates Inc. to include treatment ... aortic transection). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... endovascular graft approved by the FDA to treat a ...
... CHAPEL HILL, N.C., Jan. 13, 2012  Facing patent cliffs ... alliances - either through in-licensing deals or M&A activities ... It,s a sound strategy, but a difficult one to ... and consummating a business is fraught with potential pitfalls. ...
Cached Medicine Technology:FDA Expands Use of Endovascular Graft to Treat Aortic Tears 2Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
45 degree, forward 3 mm, 4 mm x 5 mm cup, length of shaft 140 mm, overall length 8.3 inches....
22 mm. Plastic, methylmethacrylate, lightweight. Supplied sterile....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
Medicine Products: